B+
Bull case
25%
Probability
Target price
$45.00
+94.4% vs current
SRZN
SurrozenBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$33.00
+42.6% vs current
B-
Bear case
30%
Probability
Target price
$22.00
-4.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-22
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+90.8
Score
AI commentary
Sentiment is cautious-neutral rather than outright bullish. The March 23, 2026 update improved the story with a reiterated H2 2026 IND target, a May 4, 2026 ARVO presentation, and a Boehringer Ingelheim milestone notice, but the deterministic prior remains only neutral with low catalyst density and middling evidence quality. With forward visibility still centered on preclinical progress and financing contingencies, SRZN looks more like a monitored setup than a high-conviction long [#8-K-2026-03-23] [#10-K-2026-03-23].
RankAlpha Sentiment Codex - 2026-04-22
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-04catalystARVO poster on SZN-8141 preclinical retinal dataHigh impact
Surrozen said it plans to present a poster at the 2026 ARVO Annual Meeting on May 4, 2026 covering Wnt signaling activation with VEGF inhibition in preclinical retinal vascular disease models; the setup can help refine investor expectations for the ophthalmology platform, but absent human data the likely impact is modest [#8-K-2026-03-23].
2026-09-30eventSZN-8141 IND submission targeted for H2 2026High impact
The March 23, 2026 business update says Surrozen remains on track to submit an IND for lead ophthalmology candidate SZN-8141 in the second half of 2026. A timely filing would materially improve clinical visibility, while delay would reinforce the current low-conviction monitoring view [#8-K-2026-03-23].
2026-10-31catalystIND clearance could unlock the contingent second closing of the 2025 PIPEHigh impact
Surrozen's 2026 10-K says that if the FDA clears the SZN-8141 IND on or before October 31, 2026, the second closing of the 2025 PIPE would occur and provide an additional $95.1 million in gross proceeds, which management expects would fund multiple ophthalmology programs through initial Phase 1 safety, tolerability and efficacy studies. This is a major upside lever, but it is contingent on regulatory timing and execution [#10-K-2026-03-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-22 • Updated nightlySource: Internal modelMethodology